NCT04079712 2026-03-18Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsNational Cancer Institute (NCI)Phase 2 Active not recruiting17 enrolled 12 charts
NCT00940225 2024-04-25Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesExelixisPhase 2 Completed730 enrolled 25 charts